The data expand ACI-19626's addressable diagnostic market from FTD to ALS, a larger indication. However, the data are early-stage and preliminary. Monitor for Part 2 enrollment updates and any partnership or licensing announcements. The stock may see a modest positive reaction, but the lack of concrete financial or regulatory catalysts limits upside.
Price Chart
Executive Summary
AC Immune presented Phase 1 data at the 2026 TDP43 Summit showing its TDP-43 PET tracer ACI-19626 detects higher uptake in ALS patients' brains, expanding the tracer's potential beyond FTD. The data are preliminary and from a small sample, but support the diagnostic platform's broader applicability across TDP-43 proteinopathies. No financial figures, guidance, or regulatory milestones were disclosed.
Key Facts
- Phase 1 data show ACI-19626 tracer uptake significantly higher in brain stem and precentral gyrus of ALS patients vs. healthy controls.
- Previously reported data showed detection in genetic FTD patients; Part 2 expansion may include up to 30 patients with FTD, ALS, or LATE.
- Tracer shows good safety, tolerability, and PK profile suitable for human brain imaging.
- No financial data, guidance, or regulatory milestones were provided in the release.
Financial Impact
No financial figures disclosed; potential milestone payments from partnerships exceed $4.5B but are contingent and not tied to this data.
Risk Factors
- Data are preliminary and from a small sample; results may not replicate in larger studies.
- No regulatory filing or approval timeline disclosed; clinical development is early-stage.
- AC Immune is a clinical-stage biotech with no approved products; high cash burn risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | 3/A | $2.45 $2.40 | ▼ −2.04% | ▼ −2.03% | $2.35 (−4.08%) |
Oct 9, 2026 17d ago | 3 | $2.50 $2.45 | ▼ −2.00% | ▼ −1.94% | $2.35 (−6.00%) |
Oct 2, 2026 24d ago | 6-K | $2.73 $2.71 | ▼ −0.55% | ▼ −1.22% | $2.35 (−13.76%) |
Sep 23, 2026 4w ago | 6-K | $2.83 $2.66 | ▼ −6.01% | ▼ −5.92% | $2.35 (−16.96%) |
Sep 3, 2026 7w ago | 6-K | $2.93 $2.86 | ▼ −2.39% | ▼ −2.00% | $2.35 (−19.80%) |
Aug 20, 2026 9w ago | 6-K | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.35 (−10.98%) |
Aug 20, 2026 9w ago | Press Release | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.35 (−10.98%) |
Aug 11, 2026 10w ago | 6-K | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.35 (−7.48%) |
Aug 11, 2026 10w ago | Press Release | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.35 (−7.48%) |
Aug 5, 2026 11w ago | 6-K | $2.29 $2.32 | ▲ +1.31% | ▲ +1.47% | $2.35 (+2.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers